SUVEN

New Filing detected. See link for details.

New Filing detected. See link for details.

- Allotment of 1,85,70,133 equity shares to non-promoter entities upon warrant conversion at ₹134/share, raising ₹248.83 Cr and increasing paid-up capital. - Re-appointment of Dr. Vajja Sambasiva Rao as an Independent Director for a second 5-year term (Jan 2027 - Jan 2032), subject to AGM approval. - Incorporated "Suven Neurosciences Pte. Ltd." as a 100% Wholly Owned Subsidiary in Singapore for bio-pharmaceutical clinical development, with an investment up to USD 100 Mn.

- Board approved preferential allotment of 1.86 Cr shares (₹248.84 Cr) on conversion of warrants. - Re-appointed Dr. Vajja Sambasiva Rao as an Independent Director for a second 5-year term. - Incorporated Suven Neurosciences Pte. Ltd. in Singapore as a Wholly Owned Subsidiary with a USD 100 Mn investment for bio-pharmaceutical R&D.

- Board on July 08, 2026, approved 1.85 Cr equity shares preferential allotment at ₹134/share, raising ₹248.83 Cr. - Re-appointed Dr. Vajja Sambasiva Rao as Independent Director. - Incorporated Suven Neurosciences Pte. Ltd., a 100% WOS in Singapore, with a USD 100 Mn investment.

- Board approved allotment of 1.85 Cr equity shares via warrant conversion, raising ₹248.84 Cr. - Re-appointed Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term. - Incorporated Suven Neurosciences Pte. Ltd. in Singapore as a WOS with a planned investment of USD 100 Mn.

- The Board approved the allotment of 1,85,70,133 equity shares on a preferential basis at ₹134 per share, upon conversion of warrants, raising ₹248.84 Crores and increasing paid-up capital. - Re-appointed Dr. Vajja Sambasiva Rao as a Non-Executive Independent Director for a second 5-year term from January 21, 2027, subject to AGM approval. - Approved the incorporation of Suven Neurosciences Pte. Ltd. as a Wholly-Owned Subsidiary in Singapore with a total investment of USD 100 million.

- Trading window for designated persons will close from July 1, 2026. - It will remain closed until 48 hours after the declaration of un-audited financial results for the quarter ended June 30, 2026. - The date of the Board Meeting for considering these results will be communicated later.

- Suven Life Sciences Limited allotted 2,71,970 equity shares on June 22, 2026, upon exercise of vested ESOPs at Rs. 55/- per share. - The company's paid-up equity capital increased from 26,37,20,583 to 26,39,92,553 shares.

- Suven Life Sciences will showcase its differentiated CNS clinical candidates and partnering strategies at the BIO International Convention 2026 (June 22-25). - Key highlights include positive Phase 2b results for Ropanicant and promising Phase-1 data for SUVN-I6107, alongside progress in Phase-3 programs for Masupirdine and Samelisant. - The company aims to explore strategic partnering and co-development initiatives with global pharmaceutical companies.

- Suven Life Sciences announced positive topline results from its Phase-2b clinical proof-of-concept trial of Ropanicant for the treatment of Major Depressive Disorder. - Ropanicant demonstrated clinically meaningful improvement and was generally well-tolerated. - A global Phase-3 registrational study in MDD is being planned. - A priority patent application has been filed.

- Suven Life Sciences announced the successful completion of the First-in-Human (FIH) Phase-1 clinical study for SUVN-16107. - The study demonstrated a favorable safety profile and robust pharmacodynamic activity. - SUVN-16107 is now advancing into Phase-2 clinical development.

- Suven Life Sciences announced three poster presentations on Samelisant (SUVN-G3031) at the SLEEP-2026 Annual Meeting in Baltimore, USA, from June 14-17, 2026. - Presentations will showcase positive Phase 2 efficacy data for excessive daytime sleepiness (EDS) and outline the global Phase-3 AWAKE Narcolepsy Study for Samelisant.